AVIDITY BIOSCIENCES INC (RNA) Stock Analyst Ratings
USA - NASDAQ:RNA - US05370A1088 - Common Stock
70.55 USD
+0.71 (+1.02%)
ChartMill assigns a Buy % Consensus number of 74% to RNA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 72.55. This target is 2.83% above the current price.
RNA was analyzed by 19 analysts. The buy percentage consensus is at 74. So analysts seem to be have mildly positive about RNA.
In the last month the buy percentage fell by 11 points. So the trust of analysts is decreasing.
RNA was analyzed by 19 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-11 | Chardan Capital | Maintains | Neutral -> Neutral |
| 2025-10-29 | TD Cowen | Downgrade | Buy -> Hold |
| 2025-10-28 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2025-10-28 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2025-10-27 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2025-10-27 | Bernstein | Downgrade | Outperform -> Market Perform |
| 2025-10-27 | Needham | Downgrade | Buy -> Hold |
| 2025-10-27 | Raymond James | Downgrade | Strong Buy -> Market Perform |
| 2025-10-27 | Citigroup | Downgrade | Buy -> Neutral |
| 2025-10-27 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-09-22 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-09-17 | Roth Capital | Initiate | Buy |
| 2025-09-15 | B of A Securities | Maintains | Buy -> Buy |
| 2025-09-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-10 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-09-10 | Needham | Maintains | Buy -> Buy |
| 2025-08-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-08 | Barclays | Maintains | Overweight -> Overweight |
| 2025-08-08 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-07-10 | Goldman Sachs | Reiterate | Buy |
| 2025-06-27 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-06-17 | Wolfe Research | Initiate | Outperform |
| 2025-06-11 | Raymond James | Initiate | Strong Buy |
| 2025-06-10 | Barclays | Maintains | Overweight -> Overweight |
| 2025-06-10 | Citigroup | Maintains | Buy -> Buy |
| 2025-06-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-06-09 | B of A Securities | Maintains | Buy -> Buy |
| 2025-05-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-07 | Chardan Capital | Maintains | Buy -> Buy |
AVIDITY BIOSCIENCES INC / RNA FAQ
What do analysts expect the price target to be for AVIDITY BIOSCIENCES INC (RNA)?
19 analysts have analysed RNA and the average price target is 72.55 USD. This implies a price increase of 2.83% is expected in the next year compared to the current price of 70.55.
How do analysts rate AVIDITY BIOSCIENCES INC (RNA)?
The consensus rating for AVIDITY BIOSCIENCES INC (RNA) is 73.6842 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for RNA stock?
The number of analysts covering AVIDITY BIOSCIENCES INC (RNA) is 19.